Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Early detection of ovarian cancer using group biomarkers.

Tchagang AB, Tewfik AH, DeRycke MS, Skubitz KM, Skubitz AP.

Mol Cancer Ther. 2008 Jan;7(1):27-37. doi: 10.1158/1535-7163.MCT-07-0565. Epub 2008 Jan 9.

2.

Early detection of ovarian cancer.

Badgwell D, Bast RC Jr.

Dis Markers. 2007;23(5-6):397-410. Review.

3.

Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR-FTIR spectroscopy coupled with variable selection methods.

Lima KM, Gajjar KB, Martin-Hirsch PL, Martin FL.

Biotechnol Prog. 2015 May-Jun;31(3):832-9. doi: 10.1002/btpr.2084. Epub 2015 Apr 29.

PMID:
25832726
4.

Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.

Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S.

Int J Cancer. 2004 Oct 20;112(1):14-25.

5.

Differential gene expression in ovarian carcinoma: identification of potential biomarkers.

Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR Jr, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP.

Am J Pathol. 2004 Aug;165(2):397-414.

6.

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V.

Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.

7.

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB, Hennessy BT.

Mol Cancer. 2014 Oct 24;13:241. doi: 10.1186/1476-4598-13-241.

8.

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A.

Gynecol Oncol. 2008 Sep;110(3):374-82. doi: 10.1016/j.ygyno.2008.04.041. Epub 2008 Jun 27.

PMID:
18584856
9.

Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.

Chien J, Fan JB, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V, Hartmann LC.

Gynecol Oncol. 2009 Jul;114(1):3-11. doi: 10.1016/j.ygyno.2009.04.002. Epub 2009 May 1.

PMID:
19410283
10.

Detection and monitoring of ovarian cancer.

Su Z, Graybill WS, Zhu Y.

Clin Chim Acta. 2013 Jan 16;415:341-5. doi: 10.1016/j.cca.2012.10.058. Epub 2012 Nov 16. Review.

PMID:
23165217
11.

Pathway-based classification of cancer subtypes.

Kim S, Kon M, DeLisi C.

Biol Direct. 2012 Jul 3;7:21. doi: 10.1186/1745-6150-7-21.

12.

Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.

Kurosaki A, Hasegawa K, Kato T, Abe K, Hanaoka T, Miyara A, O'Shannessy DJ, Somers EB, Yasuda M, Sekino T, Fujiwara K.

Int J Cancer. 2016 Apr 15;138(8):1994-2002. doi: 10.1002/ijc.29937. Epub 2015 Dec 15.

13.
14.

Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD.

Gynecol Oncol. 2006 Nov;103(2):405-16. Epub 2006 May 24.

PMID:
16725184
15.

Ovarian cancer in Lynch syndrome; a systematic review.

Helder-Woolderink JM, Blok EA, Vasen HF, Hollema H, Mourits MJ, De Bock GH.

Eur J Cancer. 2016 Mar;55:65-73. doi: 10.1016/j.ejca.2015.12.005. Epub 2016 Jan 13. Review.

PMID:
26773421
16.

An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66.

17.

Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.

Kotowicz B, Fuksiewicz M, Sobiczewski P, Spiewankiewicz B, Jonska-Gmyrek J, Skrzypczak M, Kowalska M.

Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:141-6. doi: 10.1016/j.ejogrb.2015.09.008. Epub 2015 Sep 12.

PMID:
26398337
18.

Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples.

Fekete T, Rásó E, Pete I, Tegze B, Liko I, Munkácsy G, Sipos N, Rigó J Jr, Györffy B.

Int J Cancer. 2012 Jul 1;131(1):95-105. doi: 10.1002/ijc.26364. Epub 2011 Dec 2.

19.

Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics.

Kaja S, Hilgenberg JD, Collins JL, Shah AA, Wawro D, Zimmerman S, Magnusson R, Koulen P.

J Biomed Opt. 2012 Aug;17(8):081412-1. doi: 10.1117/1.JBO.17.8.081412.

20.

Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis.

Andersen JD, Boylan KL, Xue FS, Anderson LB, Witthuhn BA, Markowski TW, Higgins L, Skubitz AP.

Electrophoresis. 2010 Jan;31(4):599-610. doi: 10.1002/elps.200900441.

Supplemental Content

Support Center